CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for a Phase 1 study under the Company’s Investigational New Drug (IND) application for RHX-317, a MALT1 inhibitor. The Phase 1 clinical trial in healthy volunteers will assess the safety, pharmacokinetics and pharmacodynamic responses of RHX-317 as a novel therapeutic strategy to treat autoimmune and inflammatory diseases, including chronic graft-versus-host disease (cGVHD). The trial is expected to initiate in 2H 2022.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, announced that Dania Rabah, PhD, the company’s Chief Scientific Officer, will deliver a keynote address today at the American Association for Pharmaceutical Scientists (AAPS) National Biotechnology Conference being held this week in Anaheim, CA. The keynote presentation is entitled “A New Era of Precision Medicine for Autoimmune and Inflammatory Diseases” and is featured as part of the conference’s session on new modalities in drug innovation.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced the peer-reviewed publication of preclinical data supporting MALT1 inhibition as a novel therapeutic strategy to treat autoimmune and inflammatory diseases. The new findings were published in Frontiers in Immunology in a paper titled “Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled from Effects on Regulatory T cells.” The published data demonstrate that a MALT1 inhibitor drug can be designed to achieve efficacy by inhibiting the activity of multiple immune cell types to treat autoimmune and inflammatory disease, while avoiding the reduction in beneficial regulatory T cells (Tregs).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced that it has appointed Soumya Raychaudhuri, M.D., Ph.D., and Cornelia Weyand, M.D., Ph.D., to its Scientific Advisory Board (SAB). They will join the other scientific founders and advisors who provide expert insight and guidance, complementing the company’s deep internal R&D expertise.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced the appointment of Katerina Leftheris, Ph.D., as Senior Vice President of Drug Discovery, and Nabil Uddin, Pharm.D., as Vice President of Strategy and Business Development.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced new preclinical data supporting MALT1 inhibition as a novel approach for the treatment of chronic Graft-Versus-Host Disease (cGVHD) and the use of differential metabolic pathway analysis to subset patients in this heterogeneous population. Rheos’s lead product candidate, RHX-317, is a novel, small molecule MALT1 inhibitor initially in development for the treatment of chronic GVHD. The data will be presented at the 63rd Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta and virtually, December 11-14, 2021.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced it will present preclinical data showing the potential for MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in person in Atlanta from December 11-14, 2021. The results demonstrating MALT1 inhibition support Rheos’s lead product candidate, RHX-317, a novel, small molecule MALT1 inhibitor, that the company is initially developing for the treatment of chronic GVHD with potential for other autoimmune and inflammatory diseases.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, today announced new preclinical data showing the potential for MALT1 inhibitors for the treatment of autoimmune and inflammatory diseases, as well as the power of metabolic signatures to define patient subpopulations in these heterogeneous diseases. The results demonstrating MALT1 inhibition support Rheos’s lead product candidate, RHX-317, a novel, small molecule MALT1 inhibitor, that the company is initially developing for the treatment of chronic graft versus host disease (GVHD). The data will be presented at ACR Convergence 2021, the annual meeting of the American College of Rheumatology, which will be held virtually from November 3-9, 2021.
CAMBRIDGE, Mass. & MARSEILLE, France--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory disease, today announced a research collaboration with the French non-profit research organization CRYOSTEM. The goal of the research collaboration is to provide biological resources from HSCT (Hematopoietic Stem Cell Transplantation) patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease (GvHD), based on functional immunologic profiling of patients and identification of molecular signatures for MALT1 activity. This collaboration supports a precision medicine approach to enable the treatment of GvHD, by defining the predominant metabolic pathways in the anabolic hub that drive key pathogenic pathways in GvHD patient subsets.
STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with Rheos Medicines, Inc., a US-based biopharmaceutical company, has been made public.